JACC is pleased to present an interview focusing on two papers presented at CRT. Listen in to JACC Executive Associate Editor Karthik Murugiah, MD, FACC, speak with authors Martin Frydland, MD, PhD, and Helle Søholm, MD, PhD, on their paired DOBERMANN-D and DOBERMANN-T trial research. The trials tested early low-dose dobutamine and the IL 6 inhibitor tocilizumab in high-risk STEMI patients to prevent progression to cardiogenic shock. The studies found no difference in the primary outcome (peak NT proBNP), but demonstrated feasibility and safety, with a transient reduction in NT proBNP at 12 hours in the tocilizumab arm, helping inform the design of future prevention-focused shock trials.